Literature DB >> 20183428

A seamless phase II/III design with sample-size re-estimation.

Wolfgang Bischoff1, Frank Miller.   

Abstract

A main objective in clinical trials is to find the best treatment in a given finite class of competing treatments and then to show superiority of this treatment against a control treatment. Traditionally, the best treatment is estimated in a phase II trial. Then in an independent phase III trial, superiority of this treatment, estimated as best in the first trial, is to be shown against the control treatment by a size alpha test. In this paper we investigate a competing adaptive two-stage test procedure for a seamless phase II/III trial. We assume that the variance is unknown and include therefore the calculation of the total sample size based on the first-stage-variance estimation. We derive formulae for the expected number of patients. These formulae depend on the unknown variance only, not on the other unknown parameters. Using a prior for the unknown variance, we can determine the two-stage test procedure of size alpha and power 1 - beta that is optimal in that it needs a minimal number of observations. The results are illustrated by a numerical example that indicates the superiority of the adaptive procedure over the traditional approach.

Entities:  

Mesh:

Year:  2009        PMID: 20183428     DOI: 10.1080/10543400902963193

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  2 in total

1.  Adaptive clinical trial designs in oncology.

Authors:  Yong Zang; J Jack Lee
Journal:  Chin Clin Oncol       Date:  2014-12

2.  Sample size re-assessment leading to a raised sample size does not inflate type I error rate under mild conditions.

Authors:  Per Broberg
Journal:  BMC Med Res Methodol       Date:  2013-07-19       Impact factor: 4.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.